1416334-69-4

Basic information

• Product Name: GSK-A1
• Synonyms: GSK-A1
• CAS NO: 1416334-69-4
• Molecular Formula: C₂₉H₂₇FN₆O₄S
• Molecular Weight: 574.6258832
• Mol File: 1416334-69-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: GSK-A1(CAS DataBase Reference)
• NIST Chemistry Reference: GSK-A1(1416334-69-4)
• EPA Substance Registry System: GSK-A1(1416334-69-4)

Safety Data

• Hazardous Substances Data: 1416334-69-4(Hazardous Substances Data)

Usage

Description

GSK-A1 is a chemical compound that functions as a selective and potent inhibitor of the protein kinase TBK1. It specifically inhibits TBK1-mediated phosphorylation of IRF3, a transcription factor involved in the immune response. GSK-A1 has demonstrated antiviral activity by blocking the induction of type I interferon and proinflammatory cytokines, which are crucial components of the innate immune response to viral infections. This makes GSK-A1 a promising therapeutic agent for the treatment of viral diseases or inflammatory conditions mediated by TBK1. Its unique mechanism of action and selectivity also make it a valuable tool for studying the role of TBK1 in immune signaling pathways and for developing targeted therapies for immune-related disorders.

Uses

Used in Pharmaceutical Industry:
GSK-A1 is used as a therapeutic agent for the treatment of viral diseases or inflammatory conditions mediated by TBK1. Its antiviral activity and ability to block the induction of type I interferon and proinflammatory cytokines make it a potential candidate for developing targeted therapies for immune-related disorders.
Used in Research and Development:
GSK-A1 is used as a valuable tool for studying the role of TBK1 in immune signaling pathways. Its selectivity and unique mechanism of action allow researchers to gain insights into the molecular mechanisms underlying immune responses and to identify potential targets for the development of new therapeutic agents.
Used in Drug Discovery and Development:
GSK-A1 is used as a lead compound in the discovery and development of new drugs targeting TBK1-mediated pathways. Its potent inhibitory activity and selectivity make it an attractive starting point for the design and optimization of novel therapeutic agents with improved efficacy and safety profiles.
Used in Immunology and Immunotherapy:
GSK-A1 is used as a research tool to investigate the role of TBK1 in immune responses and to explore the potential of targeting TBK1 for the development of immunotherapies. Its ability to modulate immune signaling pathways may provide new avenues for the treatment of immune-related disorders and the enhancement of immune responses against pathogens.
Used in Virology and Antiviral Research:
GSK-A1 is used as an antiviral agent to study the mechanisms by which it inhibits viral replication and the induction of type I interferon and proinflammatory cytokines. This knowledge can contribute to the development of new antiviral strategies and the identification of novel targets for the treatment of viral infections.

Upstream product

• 1416336-38-3 (2-amino-5-bromophenyl)[4-(4-morpholinyl)phenyl]amine 
• 1416336-37-2 (5-bromo-2-nitrophenyl)[4-(4-morpholinyl)phenyl]amine 
• 1383992-92-4 N-(2-fluorophenyl)-2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-sulfonamide 
• 1416336-39-4 6-bromo-1-(4-morpholinophenyl)-1H-benzo[d]imidazol-2-amine 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 2524-67-6 4-morpholino-4-yl-phenylamine 

Relevant articles and documents

BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS

Provided are compounds of Formulas I, II, III, IV, V, and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).